Onco Actu du 7 septembre 2015

	3.1 Tabac
Pfizer's quit-smoking drug not linked to depression or heart risks [Reuters] In a study tracking 150,000 smokers in England for 6 months, researchers found that patients who took Chantix, known generically as varenicline and marketed as Champix in Europe, were no more likely to suffer a heart attack than those using nicotine replacement therapy or another quit-smoking drug.
High schoolers use e-cigarettes to vape marijuana: U.S. study [Reuters] Nearly one in five high school students who said they used electronic cigarettes to vaporize nicotine also used them to vaporize pot, according to a survey of nearly 4,000 Connecticut teens.
	4. Dépistage, diagnostic et pronostic
Preventing Overdiagnosis 2015 [HealthNewsReview] My talk was on “The role of the media in preventing or promoting overdiagnosis.” My slides are now posted on SlideShare.
	5. Traitements
NICE joins project to make development of new treatments more efficient [NICE] Called the Accelerated Development of Appropriate Patient Therapies (ADAPT SMART), and funded by the EU Innovative Medicines Initiative, the project is a collaboration between 32 international partners that includes regulators, patients, academia, and industry representatives.
	5.12 Immunothérapies
CAR-T Follow Up [In the Pipeline] So there’s definitely something major here, and definitely room to improve it.
	5.2 Pharma
Genzyme vets raise $37.5M for a new cancer biotech [FierceBiotech] The stealthy X4 Pharmaceuticals, run by some of former Genzyme execs, has raised $37.5 million to fund its work on new cancer treatments.
AstraZeneca to update on leading lung cancer portfolio at WCLC 2015 [AstraZeneca] Presentations will feature 25 abstracts (including 9 oral and 4 late breaker presentations) on the company’s lung cancer pipeline, designed to address the unmet needs of patients with different forms of lung cancer.
	5.2.1 Pharma - Partenariats
Horizon to Advance Redx's Pan-RAF Inhibitors against Cancer [GEN] Horizon Discovery Group will join Redx Pharma in advancing the latter’s pan-rapidly accelerated fibrosarcoma (pan-RAF) inhibitor program, with future licensing for colorectal cancer and other oncology indications to a big pharma in mind, the companies said today.
	5.2.3 Pharma - économie
Celgene threatens to scale back UK clinical trial investment after CDF snub [Pharmafile] One of the world’s leading pharma companies in oncology is considering whether to continue investing in clinical trials in the UK, as it cannot justify the expenditure in the face of cuts to the Cancer Drugs Fund.
	5.3.4 Traitements - AMM (FDA, EMA)
Novartis wins EU approval for multiple myeloma drug Farydak [Reuters] Novartis received similar approval for Farydak from the U.S. Food and Drug Administration in February for treating multiple myeloma, a form of blood cancer that arises from plasma cells found in bone marrow.
	5.4 Traitements - Economie
Webinar: Experts Discuss Soaring Drug Prices And How Reporters Can Cover The Story [Reporting on Health] Another suggestion is that prices may be high, but at least they’re rational. But that’s not always the case, Bach said, pointing to a slide that illustrated two cancer drugs approved this year — Farydak and Ibrance — that differ in everything from reductions in deaths achieved to side effects. Yet despite the drugs’ clearly disparate results, they both cost about $10,000 a month.
Twenty-three therapies axed from Cancer Drugs Fund [PharmaTimes] the distressing de-listing process could have been avoided “if NICE and NHS England had transitioned earlier to a more appropriate, sustainable solution for evaluating and approving cancer medicines for routine use,” argues Alison Clough, the Association of the British Pharmaceutical Industry’s acting chief executive.
Cancer drugs fund cuts 23 treatments [BC News] The Cancer Drugs Fund in England will no longer pay for 16 medicines, used in 23 separate cancer treatments.
Cancer charities condemn NHS England for axing medicines [The Guardian] Decision to stop paying for drugs for leukaemia, multiple myeloma and breast, bowel, pancreatic and cervical cancer described as ‘hammer blow’.
	6. Lutte contre les cancers
World Conference on Lung Cancer Opens with Focus on Global Collaboration [Colorado Cancer Blogs] “We all share one goal: conquering the lung and thoracic cancers that account for nearly a third of all cancer deaths worldwide – more than breast, prostate and colon cancers combined,” said Dr. Fred R. Hirsch, CEO of the International Association for the Study of Lung Cancer (IASLC), University of Colorado Cancer Center member, professor of Medicine and Pathology at the University of Colorado School of Medicine and Conference President.
Dr Giles Maskell: ‘waiting a month or more for scan results is shocking’ [Cancer Research UK] Dr Giles Maskell is a consultant radiologist in Truro, and President of the Royal College of Radiologists. Here, he shares his reaction to our new report on medical imaging services, published today.
Tests to diagnose cancer underfunded and staff overstretched [Cancer Research UK] The reports highlight the growing pressures on services for imaging and endoscopy – a test that uses a camera to look inside parts of the body. And, as the number of new cancer cases continues to rise, the demand for these diagnostic tests will grow.
Breast cancer care quality threatened by lack of specialist nurses [The Guardian] While new cases of the cancer rose from 38,153 in 2003 to 44,831 in 2013, the number of breast cancer nurses had remained the same at 434 since records started in 2007.
	6.6 Publications
Investigation leads to retraction of breast cancer paper, second for one author [Retraction Watch] The authors of a Journal of Biological Chemistry paper on a breast cancer gene are withdrawing it following an investigation at Roswell Park Cancer Institute that found a figure contained “manipulated” data.
	6.9 Controverses
UT Chancellor Mandates Unprecedented Shared Governance Structure at MD Anderson [The Cancer Letter] The new structure, instituted Sept. 1, disbands the once powerful Executive Committee, thereby changing the cancer center’s top-down power structure.